To understand the biogenesis of extracellular vesicles, it is crucial to explore the different types of EVs characterized in the literature: exosomes, microvesicles, and apoptotic bodies. Each type originates from distinct cellular processes, including endocytosis and membrane shedding, and varies in size, lipid composition, and protein cargo. Exosomes, for instance, are small vesicles (30-150 nm) formed within multivesicular bodies before being released into the extracellular space, serving as vital mediators of cellular communication.

The mechanism of EV formation starts in the endosomal pathway, where intraluminal vesicles are produced. These vesicles contain a variety of biomolecules such as proteins, lipids, and RNA, which can reflect the physiological state of the parent cells. Once the multivesicular bodies fuse with the plasma membrane, they release exosomes into the surrounding environment, thus facilitating signaling between neighboring and distant cells. This biogenesis process underscores the capacity of EVs to carry functional cargo that can influence recipient cells profoundly.

Examining the effects of EVs on the immune microenvironment reveals a complex tapestry of interactions. Tumor-derived EVs can modulate immune cell functions, often promoting an immunosuppressive environment that facilitates tumor growth and metastasis. They achieve this through various mechanisms, including the alteration of immune cell activation, recruitment, and differentiation. Research has shown that EVs can carry immunomodulatory molecules, such as programmed death-ligand 1 (PD-L1) and various cytokines, directly affecting the behavior of T cells and myeloid cells.

Moreover, specialized studies have illustrated the role of EVs in the evasion of immune surveillance. Tumor cells utilize EVs to transfer inhibitory signals to T cells, subsequently leading to their dysfunction. By altering the cytokine profiles or presenting inhibitory ligands on their surfaces, tumor-derived EVs can effectively dampen the anti-tumor immune response. The interplay between EVs and immune cells is not one-directional; immune cells can also release EVs that affect tumor cells, creating a dynamic signaling network that contributes to tumor progression.

The diversity in EV composition further complicates the understanding of their functions within the tumor microenvironment. The lipid bilayer of the vesicles, along with the specific proteins and nucleic acids they carry, can dramatically change according to the tumor’s genetic makeup and environmental influences. This variability poses challenges in understanding their precise roles, necessitating advanced research methodologies for the detailed characterization of EVs.

It is also essential to consider the therapeutic implications of EVs. Because of their natural roles in cellular communication, there is a burgeoning interest in exploiting EVs for therapeutic purposes. Researchers are investigating the use of engineered EVs as drug delivery vehicles, capable of transporting anticancer drugs or genetic material to specific cells while minimizing off-target effects. These innovative approaches hold potential not only for enhancing the efficacy of cancer therapies but also for navigating the complexities of the tumor microenvironment.

Furthermore, the potential biomarkers within EVs are garnering attention as prognostic tools in oncology. Given that EVs mirror the molecular profile of their parent cells, analyzing their content may provide insights into tumor characteristics and patient prognosis. Liquid biopsies that incorporate EV analysis could revolutionize cancer diagnostics, offering a less invasive means of monitoring disease progression and treatment response.

As the research into extracellular vesicles continues to unfold, critical questions remain unanswered. Understanding the intricate signaling pathways influenced by EVs in the tumor microenvironment will be imperative for fully leveraging their therapeutic potential. Investigating how different tumor types release and utilize EVs could lead to personalized therapeutics tailored towards specific tumor characteristics and patient needs.

In closing, the ongoing studies highlight that extracellular vesicles are not mere byproducts of cellular activity but dynamic entities that play essential roles in cancer biology. The insights provided by Yeat and Chen in their comprehensive examination of EV biogenesis and function in the tumor microenvironment pave the way for future research endeavors. As we delve deeper into the world of EVs, a clearer picture of how these vesicles influence cancer progression and the immune response emerges, offering avenues for innovative therapeutic strategies.

Understanding the nuances of extracellular vesicle biology is vital for translating these findings into clinical practice. Future research will likely focus on deciphering the molecular mechanisms underlying EV-mediated interactions in diverse tumor contexts. This knowledge will not only expand our fundamental understanding of cancer biology but also inform the development of novel treatments, potentially altering the landscape of cancer therapy for future generations.

Ultimately, the incorporation of novel therapeutic strategies that leverage the unique properties of extracellular vesicles could profoundly impact the future of oncology. As the research community continues to unravel the complexities of EVs, we are poised to transform our approach to cancer treatment, underscoring the importance of understanding the communicative roles of these vesicles within the tumor microenvironment.

Through collaborative efforts across disciplines, from molecular biology to clinical oncology, the path forward in extracellular vesicle research appears promising. With ongoing technological advancements, we are equipped to unlock the full potential of EVs, ushering in a new era of precision medicine tailored to harness the power of these biological messengers.

Subject of Research: Extracellular Vesicles and Their Impact on Tumor Immune Microenvironment

Article Title: Extracellular Vesicles: Biogenesis Mechanism and Impacts on Tumor Immune Microenvironment

Article References: Yeat, N.Y., Chen, RH. Extracellular vesicles: biogenesis mechanism and impacts on tumor immune microenvironment. J Biomed Sci 32, 85 (2025). https://doi.org/10.1186/s12929-025-01182-2

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12929-025-01182-2

Keywords: Extracellular vesicles, tumor microenvironment, immunomodulation, biogenesis, cancer therapy.

Cell cycle proteins are traditionally categorized into positive and negative regulators, each with distinct functions. Positive regulators such as cyclins and CDKs catalyze progression through key cell cycle checkpoints, thereby promoting cell division. In contrast, negative regulators like p21 and p16 function as molecular brakes, restraining uncontrolled cycle progression to maintain cellular homeostasis. However, this paradigm expands considerably when viewed through the lens of cancer, where deregulated cell cycle proteins simultaneously modulate the tumor microenvironment (TME), a complex ecosystem comprising immune cells, stromal cells, signaling molecules, and extracellular matrix components.

Within the positive regulatory cadre, CDK1, CDK2, CDK5, CDK6, CDK7, CDK9, and CDK20 exhibit aberrant expression profiles across different tumor types, directly influencing the composition and functionality of immune cells within the TME. For instance, in lung adenocarcinoma, CDK1 is notably overexpressed in tumor compartments and works in tandem with the chemokine CXCL8 expressed by macrophages. This interaction fosters an immunosuppressive niche, enabling tumors to evade immune surveillance and flourish. Intriguingly, pharmacological inhibition of CDK1 disrupts this axis, downregulating CXCL8 transcription and reprogramming macrophages away from their tumor-promoting states, culminating in suppressed tumor growth.

Triple-negative breast cancer (TNBC), a notoriously aggressive basal-like subtype, holds another example where cell cycle regulation intertwines with immune evasion. Elevated levels of the cyclin E/CDK2 complex typify these tumors. The CDK2 inhibitor SNS-032 has demonstrated potent anti-cancer efficacy by inducing extensive tumor cell death, thereby releasing a cache of cellular debris that acts as a beacon recruiting cytotoxic T lymphocytes (CTLs). This recruitment invigorates the immune response against tumor cells. Additionally, SNS-032 lifts the expression of PD-L1 in residual tumor cells, paradoxically illuminating susceptibility to immune checkpoint blockade. When combined with the anti-PD-L1 antibody avelumab, SNS-032 potentiates natural killer (NK) cell cytotoxicity via antibody-dependent mechanisms, effectively orchestrating a multipronged immune assault.

The interplay between cell cycle proteins and immune checkpoint pathways further manifests in medulloblastoma. Here, interferon-γ (IFN-γ) provokes PD-L1 expression through a complex regulatory nexus involving CDK5. IFN-γ not only triggers PD-L1 transcription via IRF-1 but simultaneously upregulates p35, an activator of CDK5. This activation diminishes the repressive influence of the IRF2/IRF2BP2 complex on PD-L1 gene expression, allowing tumor cells to escape immune destruction. Genetic ablation of CDK5 in experimental models results in decreased PD-L1, increased infiltration of cytotoxic CD8+ T cells, and a reduction in regulatory T cells (Tregs), collectively tipping the balance toward immune-mediated tumor elimination.

Expanding the scope, the review accentuates that through cell cycle-associated signaling, diverse immune subsets—ranging from dendritic cells (DCs) and macrophages to myeloid-derived suppressor cells (MDSCs) and T cell subsets—are dynamically modulated. For example, negative regulators like p21 function beyond cell cycle arrest, acting as enhancers of immunosurveillance by promoting the senescence-associated secretory phenotype (SASP), which can either support or hinder anti-tumor responses depending on context. Similarly, the lincRNA-p21 in tumor-associated macrophages (TAMs) serves as a pivotal switch, where its knockdown encourages M1 macrophage polarization, a phenotype conducive to tumor suppression.

The therapeutic implications of targeting these molecular regulators have gained substantial momentum. A suite of CDK inhibitors, each with unique specificity profiles, has traversed from bench to bedside. Trials with pan-CDK2 inhibitors such as SNS-032, CDK4/6 inhibitors including abemaciclib and palbociclib, as well as CDK7 inhibitors like YKL-5-124, demonstrate that impairing cell cycle machinery can recondition the immunological milieu. Such interventions may transform immunologically “cold” tumors—those refractory to immune activation—into “hot” tumors endowed with robust immune infiltrates.

Crucially, combination strategies augment these effects, integrating CDK inhibition with immune checkpoint blockade or other targeted therapies. The synergy is evident in preclinical models where concurrent modulation leads to enhanced tumor regression and prolonged survival. Moreover, personalized therapeutic regimens mindful of the tumor’s unique CDK profile promise precision medicine approaches that optimize efficacy while curbing adverse effects.

This review also underlines the necessity of dissecting cell cycle protein function within different cellular compartments of the TME, given that the same protein may elicit divergent effects depending on contextual cues. Such nuanced understanding is indispensable for refining therapeutic targets and anticipating resistance mechanisms that tumors inevitably deploy.

By bridging cancer cell proliferation with immune regulation, cell cycle proteins emerge not solely as drivers of tumor growth but as lynchpins of immune escape and therapeutic resistance. Their dualistic nature invites innovation in drug design and immunotherapy, fostering a new era in oncology where the cell cycle is both a target and a biomarker.

In summary, the comprehensive synthesis provided by researchers at Anhui Medical University elucidates the multifaceted roles of cell cycle proteins in sculpting the tumor immune microenvironment. It heralds an exciting frontier where cyclin-dependent kinases — long recognized for cell cycle governance — are harnessed as modulators of anti-tumor immunity. With ongoing clinical validation of CDK inhibitors and their combinatorial use with immunotherapies, the future portends significant advances in effective cancer treatment, offering hope to patients confronting some of the most challenging malignancies.

Subject of Research: The regulatory effects of cell cycle proteins on the tumor immune microenvironment and implications for anti-tumor immunity.

Article Title: The roles of cell cycle proteins in regulating the tumor immune microenvironment

News Publication Date: Not specified (to be updated upon publication)

Web References: https://www.sciencedirect.com/journal/genes-and-diseases

References: DOI: 10.1016/j.gendis.2025.101706

Image Credits: Qingbo Zhu, Xiaoli Wei, Ziting Qu, Lili Lu, Yiyin Zhang, Hua Wang

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, with prognosis heavily influenced by the tumor immune microenvironment. While existing staging systems, such as TNM classification, provide useful clinical frameworks, they often fail to capture the heterogeneity of immune interactions within the tumor milieu. Prior investigations have implicated inflammatory mediators like COX-2 and immune checkpoint molecules such as PD-L1 in modulating antitumor immunity and therapeutic responses; however, their combined prognostic value alongside T-cell infiltration has lacked clarity until now.

This study deployed a dual-pronged approach that combined an internally curated cohort of 320 CRC patients with comprehensive public genomic datasets, including GSE39582, TCGA-COAD, and E-MTAB-12862, allowing robust cross-validation of findings. Using advanced bioinformatics tools such as CIBERSORTx and single-sample gene set enrichment analysis (ssGSEA), the investigators meticulously characterized immune cell subsets and molecular signatures, stratifying tumors via consensus molecular subtypes (CMS) to contextualize immunobiological variations.

One of the pivotal revelations was that PD-L1 expression localized within the tumor stroma, rather than cancer cells per se, wielded superior prognostic influence. Stromal PD-L1 correlated strongly with elevated COX-2 levels and increased tumor-infiltrating lymphocytes (TILs), underscoring a cooperative immunoregulatory network that shapes tumor behavior. These associations were consistently observed across cohorts and mirrored by transcriptomic expression profiles of CD274 (encoding PD-L1), PTGS2 (encoding COX-2), and CD8A, which notably co-enriched in CMS1 subtype tumors known for their inflamed microenvironment.

Intriguingly, tumors with heightened PTGS2 expression exhibited an inflammatory yet paradoxically immunosuppressive microenvironment, characterized by activation of interferon gamma (IFN-γ) signaling and inflammatory response pathways. This dichotomy highlights the complex dual roles of COX-2-driven prostaglandin pathways in both fostering immune activation and promoting tolerance, a phenomenon that has significant therapeutic implications.

Survival analyses incorporating multivariate models demonstrated that integrating stromal PD-L1, COX-2, and T-cell markers into a unified immune-inflammation risk score markedly outperformed prognostication based on single markers. This composite risk signature improved predictive accuracy beyond standard TNM staging, offering a refined tool for clinical decision-making. The findings suggest that tumor immune contexture and inflammatory mediators must be evaluated in tandem to capture the nuanced biology driving colorectal cancer progression.

The mechanistic underpinnings likely involve COX-2-mediated prostaglandin synthesis fostering an immunomodulatory niche that influences PD-L1 expression on stromal cells, thereby regulating T-cell infiltration and activity. This triad constitutes a conserved immunoregulatory axis that modulates tumor-immune interactions, potentially dictating responses to immunotherapy and chemoprevention strategies. Given the advent of checkpoint inhibitors and their variable efficacy in CRC, these insights pave the way for biomarker-driven patient stratification and combinatorial therapeutic approaches.

Moreover, the enrichment of these markers within CMS1 tumors, a molecular subtype characterized by microsatellite instability and high immune infiltration, further corroborates the clinical relevance of this axis. Targeting COX-2 signaling in conjunction with PD-L1 blockade may synergistically enhance antitumor immunity, an approach warranting rigorous clinical evaluation.

This expansive research effort underscores the transformative potential of integrating immunohistochemical and transcriptomic data to decode the tumor microenvironment’s complexity. By moving beyond isolated markers to composite risk models incorporating immune checkpoints and inflammatory enzymes alongside immune cell infiltration, the study sets a new benchmark for prognostication in colorectal cancer.

Importantly, the development of an IHC-based immune-inflammation risk score facilitates translation into routine pathology workflows, ensuring accessibility and applicability in diverse clinical settings. This practical tool promises to guide personalized treatment strategies, optimizing outcomes while sparing unnecessary toxicity.

Looking ahead, these findings may inform novel clinical trials combining COX-2 inhibitors, immune checkpoint inhibitors, and T-cell modulating agents, aiming to overcome resistance mechanisms and enhance durable responses. They also suggest avenues for chemopreventive interventions targeting the COX-2/PD-L1 axis in high-risk patient populations.

In sum, this comprehensive study reveals that stromal PD-L1 and COX-2 create an immuno-inflammatory landscape that intricately governs T-cell infiltration and tumor progression in colorectal cancer. Their combined evaluation refines prognostic stratification, heralding a new era of immune-informed oncology that integrates molecular, cellular, and spatial tumor parameters.

As the oncology community increasingly embraces precision medicine, such integrative biomarkers will be key in tailoring therapies and monitoring disease trajectory. This research not only advances scientific understanding but also holds profound implications for improving patient care and outcomes in colorectal cancer.

The study, recently published in BMC Cancer, represents a significant leap forward in elucidating the complex tumor-immune dialogue and sets the stage for translational advances that leverage immune modulation as a cornerstone of effective cancer management.

Subject of Research: Integration of cyclooxygenase-2 (COX-2), stromal programmed cell death ligand 1 (PD-L1), and tumor-infiltrating lymphocytes (TILs) to enhance prognostic stratification in colorectal cancer by analyzing tumor immune microenvironment heterogeneity and developing a composite immune-inflammation risk score.

Article Title: Integrating COX-2, stromal PD-L1, and T-cell infiltration enhances prognostic stratification in colorectal cancer

Article References:
Topi, G., Sjölander, A. & Satapathy, S.R. Integrating COX-2, stromal PD-L1, and T-cell infiltration enhances prognostic stratification in colorectal cancer.
BMC Cancer 25, 1424 (2025). https://doi.org/10.1186/s12885-025-14927-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14927-x

The tumor microenvironment operates as a tense metabolic arena where cancer cells relentlessly consume available amino acids, depriving immune cells of essential substrates necessary for their activation and survival. Glutamine, for instance, is avidly taken up by tumor cells through the overexpression of the transporter SLC1A5. This increased glutamine uptake fuels the tricarboxylic acid (TCA) cycle, supporting tumor bioenergetics and biosynthesis. Concurrently, glutamine metabolism enhances the expression of programmed death-ligand 1 (PD-L1), a crucial immune checkpoint molecule that binds PD-1 receptors on CD8⁺ T cells and inhibits T cell receptor (TCR) signaling. The consequence is a suppression of cytotoxic T lymphocyte activation and the induction of T cell exhaustion, undermining antitumor immunity at a fundamental level.

Simultaneously, the depletion of glutamine in the extracellular milieu compromises T cell metabolic fitness. T cells require glutamine to maintain TCA cycle function and to support their rapid proliferation and effector capabilities. Thus, the tumor’s monopolization of glutamine creates a metabolic void that weakens immune surveillance. This insight highlights how amino acid scarcity in the TIME does not merely reflect nutrient competition but constitutes a deliberate, tumor-driven sabotage of T cell efficacy. The dual role of glutamine in both tumor promotion and immune suppression underscores its critical position as a target for therapeutic intervention designed to restore immune competence.

Tryptophan metabolism illustrates another mechanism by which tumors subvert immune function. Cancer cells overconsume tryptophan and enzymatically convert it into kynurenine via indoleamine 2,3-dioxygenase (IDO). Kynurenine acts as a ligand for the aryl hydrocarbon receptor (AhR) in T cells, initiating a signaling cascade that downregulates co-stimulatory molecules such as CD80 and CD86 while upregulating PD-1 expression. This molecular reprogramming suppresses T cell activation and reinforces an immunosuppressive microenvironment conducive to tumor growth. The tryptophan-kynurenine-AhR axis exemplifies how tumor metabolism can directly modulate immune checkpoints and cellular phenotypes to promote tolerance rather than attack.

Beyond T cells, amino acid metabolism profoundly affects macrophage polarization and function within the TIME. Serine, metabolized through the serine–glycine–one-carbon (SGOC) pathway under the control of activating transcription factor 4 (ATF4), supports nucleotide synthesis and tumor proliferation. Tumor cells elevate serine uptake to enable this biosynthetic demand, again starving immune cells of resources. Intriguingly, serine deprivation has been shown to induce M1 macrophage polarization, a phenotype associated with pro-inflammatory and antitumor activity, mediated by upregulation of insulin-like growth factor 1 (IGF1) and activation of signal transducer and activator of transcription 1 (STAT1) signaling. This suggests that manipulating serine availability could be a viable strategy to reprogram macrophages towards an immunostimulatory state.

Arginine metabolism represents another axis exploited by tumor-associated myeloid cells to suppress immunity. Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) express arginase 1 (ARG1), which catabolizes extracellular arginine, a critical amino acid for T cell activation and proliferation. The depletion of arginine in the TIME impairs T cell receptor signaling and proliferation, effectively blunting immune responses. Additionally, the production of nitric oxide (NO) by these cells further contributes to immunosuppression. Regulatory T cells (Tregs) secrete immunosuppressive cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), reinforcing the immunosuppressive milieu and sustaining tumor tolerance.

The interplay of amino acid sensing pathways underpins how immune cells detect and respond to metabolic stress within the TIME. Key sensors such as the mechanistic target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and AhR interpret fluctuations in amino acid availability, triggering intracellular signaling networks that control cell survival, proliferation, and immune evasion. Newly identified molecular sensors, including mitochondrial threonyl-tRNA synthetase 2 (TARS2) and histone deacetylase 6 (HDAC6), expand our understanding of amino acid signaling and suggest novel targets for therapeutic modulation. These sensors act as metabolic gatekeepers, linking nutrient status to epigenetic and transcriptional control of immune and tumor cell behavior.

Capitalizing on this growing knowledge, innovative therapeutic strategies are emerging to manipulate amino acid metabolism and reprogram the TIME. Glutaminase inhibitors, which block glutamine utilization in tumor cells, aim to restore glutamine levels and metabolic fitness in T cells. Similarly, arginase inhibitors prevent arginine depletion, enhancing T cell activation. Dietary interventions restricting methionine intake are under investigation for their capacity to influence DNA methylation and epigenetic programming in tumor and immune cells alike. Moreover, amino acid-loaded nanoparticles offer targeted delivery systems to modulate local nutrient composition, while microbial-based therapies leverage the gut and tumor-associated microbiota to influence amino acid availability and immune responses.

Some of the most groundbreaking advances involve the engineering of immune cells with enhanced nutrient-sensing abilities or metabolic resilience. CAR-T cells optimized for amino acid metabolism exhibit improved persistence and antitumor efficacy in nutrient-deprived microenvironments. Similarly, probiotics designed to alter amino acid metabolite profiles within the gut or tumor niche represent a frontier for modulating systemic and local immunity. These approaches reflect a paradigm shift towards metabolic immunotherapy that integrates cellular programming with microenvironmental regulation.

The insights provided by the comprehensive review from Tongji University Cancer Center position amino acid metabolism as a central language through which tumors and immune cells communicate. Interrupting this metabolic dialogue presents unprecedented opportunities to overcome immune resistance and improve cancer treatment outcomes. By combining metabolic inhibitors with established immune checkpoint blockade or adoptive cell therapies, a synergistic effect can be achieved that not only halts tumor growth but also revives exhausted immune cells.

As metabolic profiling technologies become increasingly sophisticated, the prospect of personalized cancer treatment driven by metabolic phenotyping looms. Tailoring therapies to the metabolic landscapes of individual tumors and their immune microenvironments holds promise for enhancing therapeutic specificity and minimizing off-target effects. Amino acid metabolism emerges not only as a biomarker for disease progression but also as a lever for therapeutic intervention that may redefine future standards in oncology.

In conclusion, the dynamic and reciprocal regulation of amino acid availability and sensing profoundly shapes the tumor immune microenvironment, influencing tumor progression, immune suppression, and therapeutic response. Continued research in this field is vital to unravel the molecular intricacies of metabolic competition and to translate these findings into innovative, effective cancer therapies. The expanding toolkit of metabolic and immunologic interventions heralds a new era in which harnessing amino acid pathways may unlock the full potential of antitumor immunity and improve patient survival worldwide.

Subject of Research:
Not applicable

Article Title:
Amino acids shape the metabolic and immunologic landscape in the tumor immune microenvironment: from molecular mechanisms to therapeutic strategies

News Publication Date:
24-Jul-2025

Web References:
https://www.cancerbiomed.org/content/early/2025/07/24/j.issn.2095-3941.2025.0115

References:
DOI: 10.20892/j.issn.2095-3941.2025.0115

Image Credits:
Cancer Biology & Medicine

Keywords:
Tumor microenvironments